NCCN Guideline Momentum Leverage recent NCCN guideline updates recognizing MammaPrint to position Agendia as a supplier of evidence-backed genomic testing for personalized anthracycline decisions in early-stage breast cancer, targeting oncology clinics and hospital systems that align with guideline-driven care.

ASCO Engagement Capitalize on ongoing and upcoming ASCO presentations and data releases to drive conversations with tumor boards, medical oncologists, and breast surgeons about incorporating MammaPrint and BluePrint into routine risk stratification and treatment planning.

Diverse Population Focus Highlight novel data on genomic risk and treatment disparities to opportunities with health systems serving diverse patient populations, emphasizing equity-focused outcomes and real-world evidence to support broad adoption of MP+BP in routine care.

Strategic Partnerships Explore collaborations with oncology networks, academic centers, and biomarker trials (e.g., I-SPY 2 lineage) to integrate MammaPrint/BluePrint into trial design, neoadjuvant workflows, and companion diagnostic strategies.

Market Positioning Differentiate with the only FDA-cleared microarray recurrence test and CE-marked subtyping assay, targeting mid-to-large biotech and pathology groups, payer negotiations, and CLIA-certified labs seeking validated genomic tests with strong real-world and guideline support.